Adaptive Biotechnologies (ADPT) Enterprise Value (2018 - 2026)

Adaptive Biotechnologies has disclosed Enterprise Value across 9 years of filings, most recently posting -$210.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$210.4 million, down 8.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$210.4 million (down 8.68% YoY), and the FY2025 annual result was -$220.8 million, up 0.78% from the prior year.
• Enterprise Value came in at -$210.4 million for Q1 2026 at Adaptive Biotechnologies, up from -$220.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$193.6 million in Q1 2025 to a low of -$508.1 million in Q3 2022.
• The 5-year median for Enterprise Value is -$309.0 million (2024), against an average of -$319.6 million.
• Peak annual rise in Enterprise Value reached 49.1% in 2022, while the deepest fall reached 41.17% in 2022.
• Adaptive Biotechnologies' Enterprise Value stood at -$498.3 million in 2022, then soared by 30.45% to -$346.5 million in 2023, then soared by 35.79% to -$222.5 million in 2024, then advanced by 0.78% to -$220.8 million in 2025, then increased by 4.68% to -$210.4 million in 2026.
• The last three Enterprise Value figures came in at -$210.4 million (Q1 2026), -$220.8 million (Q4 2025), and -$213.0 million (Q3 2025), per Business Quant data.